Universal flu vaccines – soon a reality?
How close are we to a universal flu vaccine? Are universal corona vaccines attainable? What are some of the main challenges facing scientists in their quest to develop these vaccines?
Listen to Dr Florian Krammer, Mount Sinai Professor in Vaccinology at the Department of Microbiology at the Icahn School of Medicine, and ESWI Board Member, expertly addressing these questions. Dr Krammer also vividly describes New York in the first few months of the COVID-19 pandemic and explains how and why he rapidly got thousands of followers on Twitter.

Nationality: Austrian
Position: Professor of Vaccinology at the Department of Microbiology at the Icahn School of Medicine at Mount Sinai (New York, USA) and Professor of Infection Medicine at the Medical University of Vienna (Austria)
ESWI member since 2022
Florian Krammer, PhD, graduated from the University of Natural Resources and Life Sciences, Vienna. He received his postdoctoral training in the laboratory of Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai, New York working on hemagglutinin stalk-based immunity and universal influenza virus vaccines.
In 2014 he became an independent principal investigator and is currently the endowed Mount Sinai Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai. He is also the co-director of the Center for Vaccine Research and Pandemic Preparedness (C-VaRPP). Furthermore, since 2024, Dr. Krammer is Professor for Infection Medicine at the Ignaz Semmelweis Institute at the Medical University of Vienna.
Dr. Krammer's work focuses on understanding the mechanisms of interactions between antibodies and viral surface glycoproteins and on translating this work into novel, broadly protective vaccines and therapeutics. The main target is influenza virus but he is also working on coronaviruses, flaviviruses, hantaviruses, filoviruses and arenaviruses. He has published more than 400 papers on these topics. Since 2019, Dr. Krammer has served as principal investigator of the Sinai-Emory Multi-Institutional Collaborative Influenza Vaccine Innovation Center (SEM-CIVIC), which develops improved seasonal and universal influenza virus vaccines that induce long-lasting protection against drifted seasonal, zoonotic and future pandemic influenza viruses.
- Next-generation seasonal influenza virus vaccines need a neuraminidase component
- Flu vaccines - advancements, challenges, and global impact
- What is the difference between monovalent and polyvalent vaccines?
- How are vaccines made?
- A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein
- The Nomadic Life of a Scientist
- Is eradication of influenza B viruses possible?
- SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
- Sequential vaccinations with divergent H1N1influenza virus strains induce multi-H1 cladeneutralizing antibodies in swine
- We need to keep an eye on avian influenza
- Universal flu vaccines – soon a reality?
- Why Are Lots of Kids Likely to Be Sick This Holiday Season?
- Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
- 8th International Influenza Meeting
- Childhood Influenza Vaccination and treatment in a COVID-19 era